Corium, Inc. is advancing its Corplex™ Donepezil transdermal delivery system (TDS) aimed at improving pharmacokinetic profiles for Alzheimer's Disease treatment. The transdermal route may enhance patient compliance compared to oral formulations, addressing a significant market need in Alzheimer's care. The study's completion in June 2018 positions Corium to leverage its findings for potential partnerships or licensing opportunities, particularly in the growing Alzheimer's therapeutics market, which is projected to expand significantly due to increasing prevalence rates. Competitive analysis indicates that while several oral formulations exist, the transdermal approach could differentiate Corium's offering, provided safety and efficacy are established.